Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long- term follow-up

Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors

The ARTIS-trial: Studying the Value of an Artificial Intelligence-based Smartphone Application for the Detection of Skin Cancer

Intratumoral BO-112 in combination with pembrolizumab in patients with melanoma and skin only metastases; subgroup analysis of BOT112-03 clinical trial

Phase III Study of Adjuvant Encorafenib Plus Binimetinib Versus Placebo In Fully Resected Stage IIB/C BRAFV600-Mutated Melanoma: COLUMBUS-AD Study Design

Real-world baseline characteristics of melanoma patients treated with adjuvant nivolumab in France (AdjuMel study)

Clinical activity of fianlimab (REGN3767), a human anti–lymphocyte activation gene-3 monoclonal antibody, combined with cemiplimab (anti–programmed cell death-1) in patients with advanced melanoma

C-POST protocol update: A Phase 3, randomised, double-blind study of adjuvant cemiplimab versus placebo post surgery and radiation therapy in patients with high-risk cutaneous squamous cell carcinoma

COMBI-EU: BRAF-/MEK-inhibition with Dabrafenib and Trametinib in melanoma patients in the adjuvant setting: interim analysis of an observational study on a treatment supporting electronic health app

Vidutolimod, a CpG-A Toll-like receptor 9 agonist delivered in a virus-like particle, ± pembrolizumab in patients with PD-1 blockade– refractory melanoma: final analysis of a phase 1b study